Paul Matteis analyst STIFEL

Currently out of the existing stock ratings of Paul Matteis, 163 are a BUY (65.99%), 84 are a HOLD (34.01%).

Paul Matteis

Work Performance Price Targets & Ratings Chart

Analyst Paul Matteis works at STIFEL with a stock forecast success ratio of 55.88% fulfilled within 206.51 days on average.

Paul Matteis’s has documented 506 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 09-May-2024.

Wall Street Analyst Paul Matteis

Analyst best performing recommendations are on AVDL (AVADEL PHARMACEUTICALS PLC).
The best stock recommendation documented was for AVDL (AVADEL PHARMACEUTICALS PLC) at 5/26/2022. The price target of $2 was fulfilled within 1 day with a profit of $0.93 (86.92%) receiving and performance score of 869.16.

Average potential price target upside

ACAD ACADIA Pharmaceuticals ACOR Acorda Therapeutics ALKS Alkermes Plc ALNY Alnylam Pharmaceuticals ALXN Alexion Pharmaceuticals ATHA Athira Pharma  BIIB Biogen BMRN Biomarin Pharmaceutical CERE Cerevel Therapeutics Holdings GWPH GW Pharmaceuticals plc IONS Ionis Pharmaceuticals KRTX Karuna Therapeutics NBIX Neurocrine Biosciences PRVL Prevail Therapeutics SAGE Sage Therapeutic VRTX Vertex Pharmaceuticals ZGNX Zogenix AVDL Avadel Pharmaceuticals PLC DYN Dyne Therapeutics  KALV Kalvista Pharmaceuticals GMTX Gemini Therapeutics QURE Uniqure NV ALEC Alector PRTK Paratek Pharmaceuticals ABOS Acumen Pharmaceuticals ELYM Eliem Therapeutics WVE Wave Life Sciences Ltd XENE Xenon Pharmaceuticals AKCA Akcea Therapeutics AKAO Achaogen CDTX Cidara Therapeutics DNLI Denali Therapeutics NBRV Nabriva Therapeutics AG OREX Orexigen Therapeutics PEPG PepGen Ltd GHRS GH Research PLC

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

22

$6.8 (44.74%)

30

16 days ago

6/7 (85.71%)

$6.75 (44.26%)

281

Buy

37

$21.8 (143.42%)

37

17 days ago

25/35 (71.43%)

$21.79 (143.26%)

486

Hold

21

$5.8 (38.16%)

39

17 days ago

7/11 (63.64%)

$5.79 (38.07%)

153

Buy

27

$11.8 (77.63%)

33

17 days ago

8/20 (40%)

$11.79 (77.51%)

119

Buy

30

$14.8 (97.37%)

36

17 days ago

0/2 (0%)

$14.79 (97.24%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Paul Matteis is most bullish on?

Potential upside of $69.19 has been obtained for BIIB (BIOGEN)

Which stock is Paul Matteis is most reserved on?

Potential downside of $4.3 has been obtained for GHRS (GH RESEARCH PLC)

What Year was the first public recommendation made by Paul Matteis?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?